NanoViricides (NNVC) 10-Q 14 Nov 16 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2016	Nov. 14, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		58,203,000

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2016	Jun. 30, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 21,912,927	$ 24,162,185
Prepaid expenses	207,563	219,458
Total Current Assets	22,120,490	24,381,643
PROPERTY AND EQUIPMENT
Property and equipment	13,636,018	13,611,583
Accumulated depreciation	(2,014,102)	(1,850,816)
Property and equipment, net	11,621,916	11,760,767
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(69,554)	(67,487)
Trademark and patents, net	389,400	391,467
OTHER ASSETS
Security deposits	3,515	3,515
Service agreements	87,348	96,026
Total Other Assets	90,863	99,541
Total Assets	34,222,669	36,633,418
CURRENT LIABILITIES:
Accounts payable	269,388	96,524
Accounts payable - related parties	658,439	767,454
Debentures payable - Series B, net of discount	5,688,609	5,474,737
Derivative liability - Series B debentures	120,123	203,030
Accrued expenses	35,649	35,602
Deferred interest payable - current portion	166,667	166,667
Total Current Liabilities	6,938,875	6,744,014
LONG TERM LIABILITIES:
Deferred interest payable - long term portion	124,999	166,667
Total Long Term Liabilities	7,058,728	6,841,190
Total Liabilities	13,997,603	13,585,204
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 58,202,708 and 58,179,699 shares issued and outstanding at September 30, 2016 and June 30, 2016, respectively	58,202	58,179
Additional paid-in capital	88,048,410	87,810,145
Accumulated deficit	(67,885,645)	(64,824,201)
Total Stockholders' Equity	20,225,066	23,048,214
Total Liabilities and Stockholders' Equity	34,222,669	36,633,418
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability	3,285,204	3,197,182
Series C Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	3,323,258	3,133,668
Derivative liability	325,267	343,673
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 4,098,810 and 4,091,094 shares issued and outstanding, at September 30, 2016 and June 30, 2016, respectively	$ 4,099	$ 4,091

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2016	Jun. 30, 2016
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	58,202,708	58,179,699
Common stock, shares, outstanding	58,202,708	58,179,699
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	8,500,000	8,500,000
Preferred stock, shares issued	4,098,810	4,091,094
Preferred stock, shares outstanding	4,098,810	4,091,094

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
OPERATING EXPENSES
Research and development	$ 1,452,137	$ 1,282,072
General and administrative	988,312	942,979
Total operating expenses	2,440,449	2,225,051
LOSS FROM OPERATIONS	(2,440,449)	(2,225,051)
OTHER INCOME (EXPENSE):
Interest income	14,176	8,825
Interest expense	(245,000)	(245,000)
Discount on convertible debentures	(403,462)	(333,710)
Change in fair value of derivatives	13,291	1,487,982
Other (Expense) income, net	(620,995)	918,097
LOSS BEFORE INCOME TAXES	(3,061,444)	(1,306,954)
INCOME TAX PROVISION	0	0
NET LOSS	$ (3,061,444)	$ (1,306,954)
NET LOSS PER COMMON SHARE
- Basic (in dollars per share)	$ (0.05)	$ (0.02)
- Diluted (in dollars per share)	$ (0.05)	$ (0.02)
Weighted average common shares outstanding
- Basic (in shares)	58,179,949	57,274,315
- Diluted (in shares)	58,179,949	57,274,315

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - 3 months ended Sep. 30, 2016 - USD ($)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AccumulatedDeficit [Member]
Balance at Jun. 30, 2016	$ 23,048,214	$ 4,091	$ 58,179	$ 87,810,145	$ (64,824,201)
Balance (in shares) at Jun. 30, 2016		4,091,094	58,179,699
Series A Preferred stock issued for employee compensation	182,898	$ 8	$ 0	182,890	0
Series A Preferred stock issued for employee compensation (in shares)		7,716	0
Common Shares issued for consulting and legal services rendered	27,000	$ 0	$ 16	26,984	0
Common Shares issued for consulting and legal services rendered (in shares)		0	16,232
Warrants issued to Scientific Advisory Board	17,148	$ 0	$ 0	17,148	0
Common Shares issued for Directors fees	11,250	$ 0	$ 7	11,243	0
Common Shares issued for Directors fees (in shares)		0	6,777
Net loss	(3,061,444)	$ 0	$ 0	0	(3,061,444)
Balance at Sep. 30, 2016	$ 20,225,066	$ 4,099	$ 58,202	$ 88,048,410	$ (67,885,645)
Balance (in shares) at Sep. 30, 2016		4,098,810	58,202,708

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,061,444)	$ (1,306,954)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation and for services	182,898	182,522
Common shares issued as compensation and for services	38,250	41,550
Warrants granted to Scientific Advisory Board	17,148	8,745
Depreciation	163,286	161,606
Amortization	2,067	2,067
Change in fair value of derivative liability	(13,291)	(1,487,982)
Amortization of debt discount on convertible debentures	403,462	333,710
Changes in operating assets and liabilities:
Prepaid expenses	11,895	50,932
Other assets	8,678	19,449
Accounts payable	172,864	(30,975)
Accounts payable - related parties	(109,015)	422,091
Accrued expenses	47	(8,920)
Deferred interest payable	(41,668)	(41,667)
NET CASH USED IN OPERATING ACTIVITIES	(2,224,823)	(1,653,826)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(24,435)	(333,664)
CASH FLOWS FROM FINANCING ACTIVITIES:
NET CHANGE IN CASH AND CASH EQUIVALENTS	(2,249,258)	(1,987,490)
Cash and cash equivalents at beginning of period	24,162,185	31,467,748
Cash and cash equivalents at end of period	21,912,927	29,480,258
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	286,667	286,667
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common Stock issued upon cashless exercise of stock options	$ 0	$ 313

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business NanoViricides, Inc. was incorporated under the laws of the State of Colorado July 25, 2000 Edot-com.com, Inc. May 12, 2005 On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). Nanoviricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005. Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 100,000,000 4,000 As a result of the Exchange transaction, the former NVI stockholders held approximately 80 On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively. NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010 the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 (adjusted for the 3.5 to 1 reverse split) The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. 2,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Summary of Significant Accounting Policies The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2016 filed with the SEC on September 16, 2016. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 filed on September 16, 2016. Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2016 September 30, 2015 Warrants 6,633,848 5,993,823 Total potentially outstanding dilutive common shares 6,633,848 5,993,823 In addition, the Company has issued Convertible Debentures to investors. Coupon interest payable quarterly related to the Series B debentures is payable in cash or shares of Common Stock at the average of the open and close value on the date such interest payment is due at the option of the Holder. The Holders have elected to receive coupon interest in cash for the three months ended September 30, 2016 and 2015. Two of these Holders of the Series B debentures are controlled by Dr. Milton Boniuk, a director of the Company. At September 30, 2016, the number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $ 3.50 1,714,286 Pursuant to the redemption provisions of the Series C Debentures, 952,381 The Company has also issued 4,098,810 3.5 14,345,835 For the three months ended September 30, September 30, 2016 2015 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (3,061,444) $ (1,306,954) Denominator for basic weighted average shares of common stock 58,179,949 57,274,315 Basic loss per share of common stock $ (0.05) $ (0.02) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (3,061,444) $ (1,306,954) Add: Income impact of assumed conversion of Debentures - - Net loss attributable to common stockholders plus assumed conversions $ (3,061,444) $ (1,306,954) Denominator for basic weighted average shares of common stock 58,179,949 57,274,315 Incremental shares from assumed conversions of Debentures payable - - Denominator for diluted weighted average shares of common stock 58,179,949 57,274,315 Diluted loss per share of common stock $ (0.05) $ (0.02) Series B and Series C debentures were excluded from the loss per share calculation for the three months ended September 30, 2016 and September 30, 2015 because the impact is anti-dilutive. In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company is currently in the process of assessing the impact of the ASU on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures. In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for annual periods beginning after December 15, 2015 and interim periods within those fiscal years. ASU 2014-16 did not have a material impact on the Company’s financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. This guidance does not have a material impact on our financial statements.

Financial Condition

Financial Condition	3 Months Ended
	Sep. 30, 2016
Financial Condition Disclosure [Abstract]
Financial Condition Disclosure [Text Block]	Note 3- Financial Condition The Company’s financial statements for the interim period ended September 30, 2016 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has an accumulated deficit at September 30, 2016 of $ 67,885,645 21,912,927 6 3.5 February 1, 2017 While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, significant stockholder and Director Eugene Seymour CEO, significant stockholder, Director TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder InnoHaven, LLC An entity owned and controlled by a significant stockholder Milton Boniuk, MD Director and significant stockholder For the Three Months Ended September 30, September 30, 2016 2015 Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 17,995 $ 7,901 As of September 30, June 30, 2016 2016 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 658,439 $ 767,454 For the Three Months Ended September 30, September 30, 2016 2015 Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2016 and June 30, 2016. $ 861,616 $ 1,016,216 As of September 30, June 30, Debentures Payable to a Director 2016 2016 Series B Convertible Debentures - Milton Boniuk $ 4,000,000 $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 5,000,000 Total Debentures Payable to a Director $ 9,000,000 $ 9,000,000 As of September 30 June 30, Debenture Interest Payable to a Director 2016 2016 Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015: Deferred interest payable - short-term $ 166,667 $ 166,667 Deferred interest payable - long-term 124,999 166,667 Total Debenture Interest Payable to a Director $ 291,666 $ 333,334 Coupon interest expense on the Series B Debentures to Dr. Milton Boniuk for the three months ended September 30, 2016 and 2015 was $ 80,000 80,000 Coupon interest expense on the Series C Debentures to Dr. Milton Boniuk for the three months ended September 30, 2016 and 2015 was $ 125,000 125,000

Property and Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property and Equipment September 30, June 30, 2016 2016 GMP Facility $ 7,996,402 $ 7,996,402 Land 260,000 260,000 Office Equipment 46,897 46,897 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,327,112 5,302,677 Total Property and Equipment 13,636,018 13,611,583 Less Accumulated Depreciation (2,014,102) (1,850,816) Property and Equipment, Net $ 11,621,916 $ 11,760,767 Depreciation expense for the three months ended September 30, 2016 and 2015 were $ 163,286 161,606

Trademark and Patents

Trademark and Patents	3 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 - Trademark and Patents September 30, June 30, 2016 2016 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (69,554) (67,487) Trademarks and Patents, Net $ 389,400 $ 391,467 Amortization expense amounted to $ 2,067 2,067

Convertible Debentures and Deri

Convertible Debentures and Derivatives	3 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 – Convertible Debentures and Derivatives Series B On February 1, 2013, the Company raised gross proceeds of $ 6,000,000 4,000,000 4 8 120,000 Additional interest was payable in restricted common stock of 571,429 571,433 The investors can convert the principal of the debentures and any accrued interest into common stock at a fixed price of $ 3.50 7 September 30, June 30, 2016 2016 Proceeds $ 6,000,000 $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) (2,735,310) 3,264,690 3,264,690 Accumulated amortization of debt discount 2,423,919 2,210,047 Debenture payable - Series B, net $ 5,688,609 $ 5,474,737 The Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” for the three months ended September 30, 2016 and 2015, in the amounts of $ 213,872 183,629 The debenture contains embedded derivatives which are not clearly and closely related to the host instrument. The embedded derivatives were bifurcated from the host debt instrument and treated as a liability. The single compound embedded derivative features valued include the: 1. Principal conversion feature at maturity based on fixed conversion price subject to standard adjustments. 2. Redemption additional interest and Redemption Warrants offering. 3. Additional Interest Shares and Interest Warrants. The Company uses a lattice model that values the compound embedded derivatives bifurcated from the Series B Convertible Debenture based on a probability weighted discounted cash flow model at September 30, 2016 and June 30, 2016. The following assumptions were used for the valuation of the compound embedded derivative at September 30, 2016 and June 30, 2016: · The balance of the Series B Convertible Debenture as of September 30, 2016 and June 30, 2016 is $ 6,000,000 · The underlying stock price was used as the fair value of the common stock. The stock price increased to $1.69 3.50 1.60 3.50 · The projected annual volatility was based on the Company historical volatility: 1 year 9/30/2016 85 6/30/2016 83 · An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% · The Company would redeem the debentures projected initially at 0 1.0 20.0 · The Holder would automatically convert the interest if the Company was not in default and its shares value would be equivalent to the cash value; · The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. · The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.90 · Even though the shares are restricted, the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series B Convertible Debenture at September 30, 2016 and June 30, 2016 was $ 120,123 203,030 Series C On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $ 5,000,000 10 0.001 5.25 10 500,000 166,667 Company paid cash interest of $ 125,000 5.25 952,381 5.25 7 619,048 6.05 On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,645,606 1,152,297 1,152,297 1,879,428 189,590 150,081 September 30, June 30, 2016 2016 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 1,354,983 1,165,393 Debenture payable - Series C, net $ 3,323,258 $ 3,133,668 The Company uses a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at September 30, 2016 and June 30, 2016. The following assumptions were used for the valuation of the compound embedded derivative at September 30 and June 30, 2016: · The balance of the Series C Convertible Debenture as of September 30, 2016 and June 30, 2016 is $ 5,000,000 · The underlying stock price was used as the fair value of the common stock; The stock price increased to $ 1.69 6.05 1.60 6.05 · The projected annual volatility was based on the Company historical volatility: 1 year 9/30/16 85 6/30/16 83 · An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% · The Holder would automatically convert the interest if the Company was not in default and its share value was equivalent to the cash value; · The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. · The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.90 · Even though the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series C Convertible Debenture at September 30, 2016 and June 30, 2016 was $ 325,267 343,673

Equity Transactions

Equity Transactions	3 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 - Equity Transactions On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Anil Diwan, the Company’s president. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 74,317 77,336 490,094 On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Eugene Seymour, the Company’s Chief Executive Officer. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 74,317 77,336 490,094 For the three months ended September 30, 2016, the Company’s Board of Directors authorized the issuance of 7,716 34,264 Date Shares Value 7/31/2016 2,572 $ 11,439 8/31/2016 2,572 11,978 9/30/2016 2,572 10,847 7,716 $ 34,264 There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred Stock at each issuance used the following inputs: a. The common stock price was in the range $ 1.74 1.54 b. The calculated weighted average number of shares of common stock in the period; c. A 53.26 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 10.25 10.81 e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 0.58 0.42 f. 21.81 21.76 83.24 86.07 0.37 0.47 In August, 2016, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 17,148 2.04 17,148 Expected life (year) 4 Expected volatility 87.09 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.00 % For the three months ended September 30, 2016, the Company’s Board of Directors authorized the issuance of 16,232 27,000 For the three months ended September 30, 2016, the Company’s Board of Directors authorized the issuance of 6,777 11,250

Stock Warrants

Stock Warrants	3 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9 - Stock Warrants Stock Warrants Stock Warrants Number of Weighted Weighted Aggregate Outstanding and exercisable at June 30, 2016 6,616,700 $ 4.96 2.55 $ 4,459 Granted 17,148 2.04 3.83 - Outstanding and exercisable at September 30, 2016 6,633,848 $ 4.95 2.05 $ 7,888 Of the above warrants, 414,284 June 30, 2017 68,577 June 30, 2018 6,065,247 June 30, 2019 68,592 June 30, 2020 17,148

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 10 – Fair Value Measurement Fair value measurements At September 30, 2016 and June 30, 2016, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures. Fair Value Measurements at September 30, 2016: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 120,123 Derivative liability – Series C debentures - - 325,267 Derivative liability – warrants - - 3,285,204 Total derivatives $ - $ - $ 3,730,594 Fair Value Measurements at June 30, 2016: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 203,030 Derivative liability – Series C debentures - - 343,673 Derivative liability – warrants - - 3,197,182 Total derivatives $ - $ - $ 3,743,885 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014 the Company issued 2,945,428 2,479,935 2,810,071 2,479,935 58,910 76,306 5,425,222 The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of September 30, 2016 and June 30, 2016 with the following assumptions: - The 5 5.25 6.05 - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. 1 Year 9/30/16 85 % 6/30/16 83 % The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative Derivative liability – liability – liability – Series B Series C warrant Beginning balance at July 1, 2016 $ 203,030 $ 343,673 $ 3,197,182 Additions during the year - - - Change in fair value (82,907) (18,406) 88,022 Transfer in and/or out of Level 3 - - - Balance at September 30, 2016 $ 120,123 $ 325,267 $ 3,285,204

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11 - Commitments and Contingencies Legal Proceedings There are no pending legal proceeding against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an employment agreement effective July 1, 2015 for a term of three years. Dr. Diwan’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 The Company and Dr. Seymour, the Company’s Chief Executive Officer and Director, entered into an employment agreement effective July 1, 2015, for a term of three years. Dr. Seymour’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $ 150,000 26,786 35,715 26,786 35,715 On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $ 150,000 35,715 35,715 26,736 On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $ 9,000 2,572 10,800 License Agreements The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2016 filed with the SEC on September 16, 2016. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 filed on September 16, 2016.
Earnings Per Share, Policy [Policy Text Block]	Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2016 September 30, 2015 Warrants 6,633,848 5,993,823 Total potentially outstanding dilutive common shares 6,633,848 5,993,823 In addition, the Company has issued Convertible Debentures to investors. Coupon interest payable quarterly related to the Series B debentures is payable in cash or shares of Common Stock at the average of the open and close value on the date such interest payment is due at the option of the Holder. The Holders have elected to receive coupon interest in cash for the three months ended September 30, 2016 and 2015. Two of these Holders of the Series B debentures are controlled by Dr. Milton Boniuk, a director of the Company. At September 30, 2016, the number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $ 3.50 1,714,286 Pursuant to the redemption provisions of the Series C Debentures, 952,381 The Company has also issued 4,098,810 3.5 14,345,835 For the three months ended September 30, September 30, 2016 2015 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (3,061,444) $ (1,306,954) Denominator for basic weighted average shares of common stock 58,179,949 57,274,315 Basic loss per share of common stock $ (0.05) $ (0.02) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (3,061,444) $ (1,306,954) Add: Income impact of assumed conversion of Debentures - - Net loss attributable to common stockholders plus assumed conversions $ (3,061,444) $ (1,306,954) Denominator for basic weighted average shares of common stock 58,179,949 57,274,315 Incremental shares from assumed conversions of Debentures payable - - Denominator for diluted weighted average shares of common stock 58,179,949 57,274,315 Diluted loss per share of common stock $ (0.05) $ (0.02) Series B and Series C debentures were excluded from the loss per share calculation for the three months ended September 30, 2016 and September 30, 2015 because the impact is anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company is currently in the process of assessing the impact of the ASU on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures. In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for annual periods beginning after December 15, 2015 and interim periods within those fiscal years. ASU 2014-16 did not have a material impact on the Company’s financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. This guidance does not have a material impact on our financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2016 September 30, 2015 Warrants 6,633,848 5,993,823 Total potentially outstanding dilutive common shares 6,633,848 5,993,823 The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for loss from continuing operations: For the three months ended September 30, September 30, 2016 2015 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (3,061,444) $ (1,306,954) Denominator for basic weighted average shares of common stock 58,179,949 57,274,315 Basic loss per share of common stock $ (0.05) $ (0.02) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (3,061,444) $ (1,306,954) Add: Income impact of assumed conversion of Debentures - - Net loss attributable to common stockholders plus assumed conversions $ (3,061,444) $ (1,306,954) Denominator for basic weighted average shares of common stock 58,179,949 57,274,315 Incremental shares from assumed conversions of Debentures payable - - Denominator for diluted weighted average shares of common stock 58,179,949 57,274,315 Diluted loss per share of common stock $ (0.05) $ (0.02)

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	For the Three Months Ended September 30, September 30, 2016 2015 Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 17,995 $ 7,901 As of September 30, June 30, 2016 2016 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 658,439 $ 767,454 For the Three Months Ended September 30, September 30, 2016 2015 Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2016 and June 30, 2016. $ 861,616 $ 1,016,216 As of September 30, June 30, Debentures Payable to a Director 2016 2016 Series B Convertible Debentures - Milton Boniuk $ 4,000,000 $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 5,000,000 Total Debentures Payable to a Director $ 9,000,000 $ 9,000,000 As of September 30 June 30, Debenture Interest Payable to a Director 2016 2016 Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015: Deferred interest payable - short-term $ 166,667 $ 166,667 Deferred interest payable - long-term 124,999 166,667 Total Debenture Interest Payable to a Director $ 291,666 $ 333,334

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: September 30, June 30, 2016 2016 GMP Facility $ 7,996,402 $ 7,996,402 Land 260,000 260,000 Office Equipment 46,897 46,897 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,327,112 5,302,677 Total Property and Equipment 13,636,018 13,611,583 Less Accumulated Depreciation (2,014,102) (1,850,816) Property and Equipment, Net $ 11,621,916 $ 11,760,767

Trademark and Patents (Tables)

Trademark and Patents (Tables)	3 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: September 30, June 30, 2016 2016 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (69,554) (67,487) Trademarks and Patents, Net $ 389,400 $ 391,467

Convertible Debentures and De23

Convertible Debentures and Derivatives (Tables)	3 Months Ended
	Sep. 30, 2016
Series B Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following table presents the balance of the Series B Debenture payable, net of discount at September 30 and June 30, 2016. The debt discount is being amortized to interest expense over the term of the debenture: September 30, June 30, 2016 2016 Proceeds $ 6,000,000 $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) (2,735,310) 3,264,690 3,264,690 Accumulated amortization of debt discount 2,423,919 2,210,047 Debenture payable - Series B, net $ 5,688,609 $ 5,474,737
Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following represents the balance of the Debenture payable – Series C, net of discount at September 30, 2016 and June 30, 2016: September 30, June 30, 2016 2016 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 1,354,983 1,165,393 Debenture payable - Series C, net $ 3,323,258 $ 3,133,668

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Sep. 30, 2016
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 87.09 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.00 %
Series A Preferred Stock [Member]
Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]	The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2016 2,572 $ 11,439 8/31/2016 2,572 11,978 9/30/2016 2,572 10,847 7,716 $ 34,264

Stock Warrants (Tables)

Stock Warrants (Tables)	3 Months Ended
	Sep. 30, 2016
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Warrants Number of Weighted Weighted Aggregate Outstanding and exercisable at June 30, 2016 6,616,700 $ 4.96 2.55 $ 4,459 Granted 17,148 2.04 3.83 - Outstanding and exercisable at September 30, 2016 6,633,848 $ 4.95 2.05 $ 7,888

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At September 30, 2016 and June 30, 2016 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at September 30, 2016: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 120,123 Derivative liability – Series C debentures - - 325,267 Derivative liability – warrants - - 3,285,204 Total derivatives $ - $ - $ 3,730,594 Fair Value Measurements at June 30, 2016: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 203,030 Derivative liability – Series C debentures - - 343,673 Derivative liability – warrants - - 3,197,182 Total derivatives $ - $ - $ 3,743,885
Schedule Of Projected Annual Volatility [Table Text Block]	The projected annual volatility for the valuation dates are: 1 Year 9/30/16 85 % 6/30/16 83 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2016: Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative Derivative liability – liability – liability – Series B Series C warrant Beginning balance at July 1, 2016 $ 203,030 $ 343,673 $ 3,197,182 Additions during the year - - - Change in fair value (82,907) (18,406) 88,022 Transfer in and/or out of Level 3 - - - Balance at September 30, 2016 $ 120,123 $ 325,267 $ 3,285,204

Organization and Nature of Bu27

Organization and Nature of Business (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Feb. 15, 2010
Product Information [Line Items]
Entity Incorporation, State Country Name	Colorado
Entity Incorporation, Date Of Incorporation	Jul. 25, 2000
Business Acquisition, Name of Acquired Entity	Edot-com.com, Inc.
Business Acquisition, Date of Acquisition Agreement	May 12, 2005
Common stock, shares issued	58,202,708	58,179,699
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Pro rata Basis	4,000
Stock Issued During Period, Shares, New Issues	80,000,000
Common stock, shares issued	100,000,000
Business Acquisition, Percentage of Voting Interests Acquired	80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred stock, shares issued			2,000,000
Preferred stock, value			$ 2,000
Convertible Preferred Stock, Terms of Conversion	The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Companys intellectual property, into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.
Stockholders' Equity, Reverse Stock Split	(adjusted for the 3.5 to 1 reverse split)

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,633,848	5,993,823
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,633,848	5,993,823

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Calculation of basic loss per share of common stock:
Net loss attributable to common stockholders	$ (3,061,444)	$ (1,306,954)
Denominator for basic weighted average shares of common stock	58,179,949	57,274,315
Basic loss per share of common stock	$ (0.05)	$ (0.02)
Calculation of diluted loss per share of common stock:
Net loss attributable to common stockholders	$ (3,061,444)	$ (1,306,954)
Add: Income impact of assumed conversion of Debentures	0	0
Net loss attributable to common stockholders plus assumed conversions	$ (3,061,444)	$ (1,306,954)
Denominator for basic weighted average shares of common stock	58,179,949	57,274,315
Incremental shares from assumed conversions of Debentures payable	0	0
Denominator for diluted weighted average shares of common stock	58,179,949	57,274,315
Diluted loss per share of common stock	$ (0.05)	$ (0.02)

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Textual) - $ / shares	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,633,848	5,993,823
Debt Instrument, Redemption, Description	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	14,345,835
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.5
Convertible Preferred Stock, Terms Of Conversion	60% or less
Preferred Stock, Shares Issued	4,098,810		4,091,094
Common Stock [Member] | Series B Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,714,286
Debt Instrument, Convertible, Conversion Price	$ 3.50
Common Stock [Member] | Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	952,381

Financial Condition (Details Te

Financial Condition (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2015
Financial Condition [Line Items]
Cash and cash equivalents	$ 21,912,927	$ 24,162,185	$ 29,480,258	$ 31,467,748
Retained Earnings (Accumulated Deficit)	$ (67,885,645)	(64,824,201)
Series B Convertible Debentures [Member]
Financial Condition [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 3.5
Debt Instrument, Maturity Date	Feb. 1, 2017
Debentures payable	$ 6,000,000	$ 6,000,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Research and development	$ 1,452,137	$ 1,282,072
Due to Related Parties	9,000,000		$ 9,000,000
Deferred interest payable - short term	166,667		166,667
Deferred interest payable - long term	124,999		166,667
Series B Convertible Debentures [Member]
Due to Related Parties	4,000,000		4,000,000
Series C Convertible Debenture [Member]
Due to Related Parties	5,000,000		5,000,000
Deferred interest payable - short term	166,667		166,667
Deferred interest payable - long term	124,999		166,667
Interest Payable	291,666		333,334
TheraCour Pharma, Inc [Member]
Net Account Payable to related party	658,439		$ 767,454
Research and development	861,616	1,016,216
Property, Plant and Equipment, Additions	$ 17,995	$ 7,901

Related Party Transactions (D33

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
Other General and Administrative Expense	$ 2,000
Series B Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	80,000	$ 80,000
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	5,000,000
Series C Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	$ 125,000	$ 125,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
GMP Facility	$ 7,996,402	$ 7,996,402
Land	260,000	260,000
Office Equipment	46,897	46,897
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,327,112	5,302,677
Total Property and Equipment	13,636,018	13,611,583
Less Accumulated Depreciation	(2,014,102)	(1,850,816)
Property and Equipment, Net	$ 11,621,916	$ 11,760,767

Property and Equipment (Detai35

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 163,286	$ 161,606

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(69,554)	(67,487)
Trademarks and Patents, Net	$ 389,400	$ 391,467

Trademark and Patents (Details

Trademark and Patents (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Trademarks And Patents [Line Items]
Amortization	$ 2,067	$ 2,067
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 2,067	$ 2,067

Convertible Debentures and De38

Convertible Debentures and Derivatives (Details) - Series B Debentures [Member]	3 Months Ended
	Sep. 30, 2016
Expected life (year)	3 years
Expected volatility	44.18%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.01%

Convertible Debentures and De39

Convertible Debentures and Derivatives (Details 1) - Series B Debentures [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Proceeds	$ 6,000,000	$ 6,000,000
Debt discount for bifurcated derivative	(2,735,310)	(2,735,310)
Net Proceeds From Issuance Of Debt	3,264,690	3,264,690
Accumulated amortization of debt discount	2,423,919	2,210,047
Debenture payable - Series B, net	$ 5,688,609	$ 5,474,737

Convertible Debentures and De40

Convertible Debentures and Derivatives (Details 2) - Series C Debentures [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Proceeds	$ 5,000,000	$ 5,000,000
Net Proceeds From Issuance Of Debt	1,968,275	1,968,275
Accumulated amortization of debt discount	1,354,983	1,165,393
Debenture payable - Series C, net	3,323,258	3,133,668
Embedded Derivative Financial Instruments [Member]
Debt discount	(1,879,428)	(1,879,428)
Series A Preferred Stock [Member]
Debt discount	$ (1,152,297)	$ (1,152,297)

Convertible Debentures and De41

Convertible Debentures and Derivatives (Details Textual) - USD ($)	Jul. 02, 2014	Feb. 01, 2013	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Feb. 01, 2016	Feb. 01, 2014
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)			$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.25
Interest Payable, Current			$ 166,667		$ 166,667
Restricted Stock [Member]
Debt Instrument [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance							571,429
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$ 3.5
Amortization of Debt Discount (Premium)			$ 213,872	$ 183,629
Proceeds from Convertible Debt		$ 6,000,000
Debt Instrument, Term		4 years
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Warrants To Be Issued In Fourth Year						571,433
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 3.50
Long-term Debt, Excluding Current Maturities, Total			$ 6,000,000		$ 6,000,000
Share Price			$ 1.69		$ 1.60
Debt Instrument, Debt Default, Description of Violation or Event of Default			An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Projected Redemption Percentage Of Time			0.00%		83.00%
Projected Annual Volatility Percentage			85.00%
Weighted Average Discount Rate, Percent			21.90%
Debt Instrument, Periodic Payment, Interest			$ 120,000
Series B Convertible Debentures [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent			$ 120,123		$ 203,030
Series B Convertible Debentures [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			20.00%
Series B Convertible Debentures [Member] | Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			1.00%
Series B Convertible Debentures [Member] | Director [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt		$ 4,000,000
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)			$ 189,590	$ 150,081
Debt Conversion, Converted Instrument, Shares Issued	187,000
Proceeds from Convertible Debt	$ 1,645,606
Repayments of Other Debt	1,152,297
Debt Instrument, Unamortized Discount	1,152,297
Debt Conversion, Converted Instrument, Amount	$ 1,879,428
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Debt Instrument, Convertible, Conversion Price	$ 5.25
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 5,000,000
Redemption On Debentures	952,381
Warrants to purchase of Common Stock	619,048
Common stock exercise price	$ 6.05
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6.05		$ 6.05
Long-term Debt, Excluding Current Maturities, Total			$ 5,000,000		$ 5,000,000
Share Price			$ 1.60		$ 3.50
Debt Instrument, Debt Default, Description of Violation or Event of Default			An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Projected Redemption Percentage Of Time					83.00%
Projected Annual Volatility Percentage			85.00%
Weighted Average Discount Rate, Percent			21.90%
Closing Common Stock Bid Price	$ 5.25
Additional Interest Rate For Warrants	7.00%		7.00%
Interest Payable, Current			$ 166,667		$ 166,667
Interest Payable			291,666		333,334
Series C Convertible Debenture [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent			325,267		343,673
Series C Convertible Debenture [Member] | Debenture Interest Paid [Member]
Debt Instrument [Line Items]
Interest Payable, Current					$ 166,667
Interest Payable			$ 500,000

Equity Transactions (Details)

Equity Transactions (Details) - Series A Preferred Stock [Member]	3 Months Ended
	Sep. 30, 2016USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	7,716
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 34,264
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 11,439
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 11,978
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 10,847

Equity Transactions (Details 1)

Equity Transactions (Details 1) - Scientific Advisory Board [Member]	3 Months Ended
	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	4 years
Expected volatility	87.09%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.00%

Equity Transactions (Details Te

Equity Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 21, 2015	Sep. 30, 2016	Sep. 30, 2015
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		75,000
Employee Benefits and Share-based Compensation		$ 34,264
Warrant [Member] | August 2019
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		17,148
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.04
Warrant [Member] | November 2019
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		17,148
Director [Member]
Class of Stock [Line Items]
Share-based Compensation, Total		$ 11,250
Restricted common stock authorized for interest payable		6,777
President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	225,000
Share-based Compensation, Total		$ 74,317	$ 77,336
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		490,094
President [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	75,000
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	225,000
Share-based Compensation, Total		74,317	$ 77,336
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 490,094
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		75,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	75,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services		$ 27,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		7,716
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Description		the converted value to common at a ratio of 1:3.5
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		53.26%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		4 years
Series A Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share Price		$ 1.74
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		10.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions		21.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		83.24%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.37%
Series A Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share Price		$ 1.54
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		10.81%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		6 months 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions		21.81%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		86.07%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.47%
Series A Preferred Stock [Member] | Employee Compensations [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		16,232

Stock Warrants (Details)

Stock Warrants (Details) - Stock Options [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	6,616,700
Number of Shares, Granted	17,148
Number of Shares, Outstanding	6,633,848	6,616,700
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.96
Weighted Average Exercise Price per share, Granted (dollars per share)	2.04
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.95	$ 4.96
Weighted Average Remaining Contractual Term (years), Granted	3 years 9 months 29 days
Weighted Average Remaining Contractual Term (years), Outstanding	2 years 18 days	2 years 6 months 18 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 7,888	$ 4,459
Aggregate Intrinsic Value, Granted (in dollars)	$ 0

Stock Warrants (Details Textual

Stock Warrants (Details Textual)	3 Months Ended
	Sep. 30, 2016shares
June 30, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	414,284
Warrants Expiration Date	Jun. 30, 2017
June 30, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,577
Warrants Expiration Date	Jun. 30, 2018
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	6,065,247
Warrants Expiration Date	Jun. 30, 2019
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,592
Warrants Expiration Date	Jun. 30, 2020
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	17,148
Warrants Expiration Date	Jun. 30, 2021

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Warrant [Member]
Derivative Liability, Noncurrent	$ 3,285,204	$ 3,197,182
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	3,730,594	3,743,885
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	120,123	203,030
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	325,267	343,673
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	$ 3,285,204	$ 3,197,182

Fair Value Measurement (Detai48

Fair Value Measurement (Details 1)	3 Months Ended
	Sep. 30, 2016
One Year Ended 6/30/2016
Fair Value Assumptions, Expected Volatility Rate	83.00%
One year ended 9/30/2016
Fair Value Assumptions, Expected Volatility Rate	85.00%

Fair Value Measurement (Detai49

Fair Value Measurement (Details 2)	3 Months Ended
	Sep. 30, 2016USD ($)
Derivative liability - Series C debentures [Member]
Beginning balance	$ 343,673
Additions during the year	0
Change in fair value	(18,406)
Transfer in and/or out of Level 3	0
Ending Balance	325,267
Derivative liability - Series B debentures [Member]
Beginning balance	203,030
Additions during the year	0
Change in fair value	(82,907)
Transfer in and/or out of Level 3	0
Ending Balance	120,123
Warrant [Member]
Beginning balance	3,197,182
Additions during the year	0
Change in fair value	88,022
Transfer in and/or out of Level 3	0
Ending Balance	$ 3,285,204

Fair Value Measurement (Detai50

Fair Value Measurement (Details Textual) - $ / shares	Sep. 13, 2013	Jan. 24, 2014	Sep. 12, 2013	Sep. 30, 2016
Class of Warrant or Right, Outstanding		2,479,935	2,810,071
Warrants Issued		2,479,935	2,945,428
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.25
Placement Agents [Member]
Warrants Issued	58,910	76,306
Warrant Expiration Term	5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.25	$ 6.05
Scientific Advisory Board [Member]
Class of Warrant or Right, Outstanding				5,425,222

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended				3 Months Ended
	Jul. 21, 2015	Jan. 31, 2015	May 30, 2013	Mar. 31, 2010	Sep. 30, 2016	Jun. 30, 2016	Feb. 15, 2010
Commitments and Contingencies [Line Items]
Common stock, shares issued					58,202,708	58,179,699
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					75,000
Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued							2,000,000
Deferred Compensation Arrangement with Individual, Shares Issued				26,736
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					3 years
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					75,000
Chief Executive Officer [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					$ 350,000
Chief Executive Officer [Member] | Year One [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					75,000
Chief Executive Officer [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					375,000
Chief Executive Officer [Member] | Year Two [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					75,000
Chief Executive Officer [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					400,000
Chief Executive Officer [Member] | Year Three [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					$ 75,000
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					225,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					4 years
Common stock, shares issued				35,715
Additional Common Stock Shares Issued				35,715
Increase In Base Salary				$ 150,000
President [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					3 years
President [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	75,000
President [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					$ 350,000
President [Member] | Year One [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					75,000
President [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					375,000
President [Member] | Year Two [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					75,000
President [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					400,000
President [Member] | Year Three [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					$ 75,000
President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					225,000
Vice President [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					4 years
Common stock, shares issued				35,715
Additional Common Stock Shares Issued				35,715
Increase In Base Salary				$ 150,000
Vice President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued				26,786
Additional Preferred Stock Shares Issued				26,786
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					3 years
Increase In Base Salary		$ 10,800	$ 9,000
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued			2,572